Brain metastases from prostate cancer: A single-center experience

Basit Öğe Kaydı
dc.contributor.authorKanyilmaz, Gul
dc.contributor.authorAktan, Meryem
dc.contributor.authorYavuz, Berrin Benli
dc.contributor.authorKoc, Mehmet
dc.date.accessioned2024-02-23T14:41:17Z
dc.date.available2024-02-23T14:41:17Z
dc.date.issued2019
dc.departmentNEÜen_US
dc.description.abstractObjective: Metastases from prostate cancer to the brain are very unusual and very few case series have been reported in the literature. Present study was performed to assess the proportion of brain metastasis from prostate cancer among other brain metastasis in men, to evaluate the distribution, pattern and magnetic resonance imaging (MRI) appearance of these metastatic lesions, and prognosis of brain metastasis in patients with prostate cancer. Material and methods: Between January 2010 and November 2016, 339 males who had received radiotherapy at our department were retrospectively reviewed. After the first evaluation of patients data, we reviewed only the patients with brain metastases from prostate cancer. We evaluated MRI characteristics of metastatic brain lesions and characteristics of the patients, tumor and treatment modalities. Results: Ten of 339 patients (2.9%) had brain metastases from prostate cancer. Sixty percent of the patients had pure intraparenchymal metastasis, 20% of the patients had pure extensive dural metastasis and 20% of them had both. Seventy-five percent of the patients with intraparenchymal metastasis had multiple metastatic lesions. The median prostate specific antigen (PSA) level was 49.40 ng/mL and the Gleason score was >= 7 in all patients. Sixty percent of the patients had distant metastasis at the time of the diagnosis of prostate cancer. Median survival time in patients with brain metastasis was 4.5 months. Conclusion: Lesions of brain metastasis from prostate cancer had a large variety of imaging presentation and it is very difficult to distinguish them from the other brain metastasis originating from other types of cancer. Presence of a disseminated disease, high PSA level and high Gleason score can be useful parameters for the prediction of brain metastasis from prostate cancer.en_US
dc.identifier.doi10.5152/tud.2018.74555
dc.identifier.endpage283en_US
dc.identifier.issn2149-3235
dc.identifier.issn2149-3057
dc.identifier.issue4en_US
dc.identifier.pmid29975631en_US
dc.identifier.scopus2-s2.0-85071198351en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage279en_US
dc.identifier.urihttps://doi.org/10.5152/tud.2018.74555
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16785
dc.identifier.volume45en_US
dc.identifier.wosWOS:000474443200008en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal Of Urologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBrain Metastasisen_US
dc.subjectMagnetic Resonance Imagingen_US
dc.subjectProstate Canceren_US
dc.subjectRadiotherapyen_US
dc.subjectSurvival Analysisen_US
dc.titleBrain metastases from prostate cancer: A single-center experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu